The rapid medical diagnostic kits market has witnessed remarkable growth in recent years, driven by the increasing demand for quick and accurate diagnostic solutions. The rapid medical diagnostic kits market is expected to grow at a CAGR of 9% during the forecast period of 2024 to 2032, fueled by the increasing emphasis on Point-of-Care Testing (POCT), global health threats, and advancements in diagnostic technologies. While challenges in test specificity and accuracy pose restraints, the market's segmentation provides valuable insights into the preferences and priorities of healthcare professionals and consumers.
The irritable bowel syndrome (IBS) treatment market is expected to grow at a CAGR of 10.5% during the forecast period of 2024 to 2032. IBS treatment plays a vital role in providing relief to individuals suffering from IBS, a gastrointestinal disorder characterized by abdominal pain, bloating, and changes in bowel habits. As of 2023, the market exhibited steady growth, driven by increased awareness of IBS and the demand for effective treatments.
The preimplantation genetic testing (PGT) market has emerged as a critical player in the realm of reproductive health and assisted reproduction technologies. The PGT market is expected to grow at a CAGR of 7.5% during the forecast period of 2024 to 2032. The PGT market is propelled by technological advancements in genetic testing, increasing maternal age, and growing awareness. However, ethical and regulatory challenges serve as significant restraints. As the industry continues to navigate these challenges and seize opportunities, it is poised for substantial growth in the coming years.
The C-reactive protein (CRP) testing market plays a crucial role in diagnosing and monitoring various health conditions, providing valuable insights into inflammation, cardiovascular diseases, autoimmune disorders, and cancer. The C-reactive protein testing market is expected to grow at a CAGR of 0.3% during the forecast period of 2023 and 2031, driven by the rising prevalence of chronic diseases, the adoption of preventive medicine, and continuous advancements in diagnostic technologies. However, regulatory challenges and quality assurance remain significant constraints.
The blood culture test market is a critical component of the medical diagnostics industry, playing a pivotal role in diagnosing various infections. The blood culture test market is expected to grow at a CAGR of 12.5% during the forecast period of 2024 to 2032, driven by the increasing prevalence of bacterial infections, advancements in diagnostic technologies, and the rising incidence of healthcare-associated infections. The time-consuming nature of traditional blood culture methods remains a notable restraint, highlighting the need for faster and more efficient diagnostic solutions.
The lung cancer diagnostics market is pivotal in the early detection and management of lung cancer, a deadly disease with high mortality rates. The lung cancer diagnostics market is expected to grow at a CAGR of 7.5% during the forecast period of 2024 to 2032. The lung cancer diagnostics market plays a critical role in addressing the rising prevalence of lung cancer globally. Key drivers include the increasing burden of lung cancer, technological advancements, and the shift toward personalized medicine.
The global market for lateral flow assays is anticipated to expand at a CAGR of 2.2% during the forecast period of 2024 to 2032. The high prevalence of infectious diseases worldwide, the rapid development of the elderly population, the rising need for point-of-care testing, and the increasing use of home-based lateral flow assay equipment are the primary factors driving the expansion of this market. On the other hand, doctors' and patients' unwillingness to adapt existing diagnostic processes, as well as the low accuracy of lateral flow assays, are the primary obstacles.
The global cancer diagnostics market to reach US$ 136.3 Bn in 2029 growing at compound annual growth rate (CAGR) of 6.1% during the forecast period from 2021 to 2029. The prime factors driving the global cancer diagnostics market is the rising prevalence of cancer worldwide. As per the World Health Organization (WHO), cancer accounted for the second leading cause of mortality, claiming to 8.8 million deaths in 2015 globally. The National Cancer Institute estimated around 1,685,210 new cancer cases in 2019 in the United States. As per the Centers for Disease Control and Prevention (CDC), cancer cases anticipated to increase by 2 million each year by 2020.
The lyme disease diagnostics market plays a pivotal role in the early detection and treatment of Lyme disease, a vector-borne illness caused by the bacterium Borrelia burgdorferi. The lyme disease diagnostics market is expected to grow at a CAGR of 3.6% during the forecast period of 2024 to 2032, driven by the increasing incidence of Lyme disease, advancements in diagnostic technologies, and growing awareness. Despite the limitations in early-stage diagnosis, PCR tests are expected to lead in terms of CAGR.
Laryngoscopes Market Is Projected to Expand At A CAGR Of 5.1% Between 2023 And 2031. Laryngoscopy refers to the medical examination of the larynx for the purpose of visualization of vocal cords, upper tracheal rings etc. Laryngoscopes are used for diagnosis of voice disorders, ENT related pain, abnormalities and airway obstruction.
The global market for diagnostic testing is expected to surpass US $350 billion by 2030, expanding at a CAGR of 9% from 2023 to 2030.
Diagnostic tests are medical examinations performed to aid in the recognition or diagnosis of any disease. These tests are crucial for the management, surveillance, and prevention of any disease. These tests increase patient care, customer security, and healthcare expenditures. According to the study Non-communicable Illnesses Important Statistics from the World Health Organization (WHO), chronic diseases will be responsible for approximately 41 million deaths annually by April 2021, or 71 percent of all deaths worldwide. Hence, diagnostic tests have proved beneficial in the prevention, identification, and diagnosis of disease, as well as in the management of chronic sickness situations. By detecting individual risk factors and early warning signs, clinical diagnostics create new opportunities for early prevention and intervention. Thus, it is projected that the industry as a whole would continue to expand as the prevalence of chronic diseases rises.
The industry is expected to be driven by the increasing popularity of decentralized healthcare systems. In addition, it is predicted that the market would expand during the forecast period as a result of leading market players' adoption of new innovations and technical advancements in the sector. As a result of these reasons, the market for point-of-care diagnostics is predicted to expand in the future years. The aging of the world's population increases the likelihood of contracting a variety of diseases, including diabetes, cancer, cardiovascular disease, obesity, and neurological disorders. The United Nations projects that by 2020, 727 million people worldwide would be 65 or older. In addition, it is estimated that by 2050, there will be more than 1.5 billion individuals aged 80 and older, which is twice as many as there are today. The predicted growth in the global elderly population during the forecast period is likely to have a substantial impact on the market.
Acute Market Reports, a market research and consulting company remains the best choice for industry participants in the diagnostics domain. Acute Market Reports' clients gain from our forward-thinking research technique, which aids in the development of well-informed business decisions. With the help of our extensive network of business partners, we are able to offer innovative strategic research solutions to our global clients.
